Fibrex Medical Research & Development Gmbh

Ikaria Development Subsidiary Two LLC

Yale University

Xiberscience Gmbh

Peter Petzelbauer

Sonja Reingruber

Rainer Henning

Jordan S Pober

Waltraud Pasteiner

Philip W Askenase

Allan G Murray

Christopher C Hughes

The present invention relates to compounds, in particular peptides which are capable of stabilizing barrier functions of epithelium and endothelium. The peptides and other compounds of the present invention are useful in the treatment and prevention of diseases or disorders associated with a localized or systemic breakdown of epithelial and endothelial barrier functions. Particular diseases and disorders to be treated and/or prevented with the peptides or other compounds, methods and uses provided herein are burns, acute lung injury (ALI), acute respiratory distress syndrome (ARDS), ventilator induced lung injury (VILI), systemic inflammatory response syndrome (SIRS), acute kidney injury (AKI), sepsis, multiorgan dysfunction syndrome (MODS), or edema.

Peptides as active agents to stabilize biological barriers

Peptides, peptidomimetics and derivatives thereof of the general formula I: in which

Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition

The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides. 

Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition

The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein Rand Rare either the same or different, wherein Rand Rare each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Zis selected from the group consisting of histidine and proline, wherein Zis selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation.

Therapeutic fibrin-derived peptides and uses thereof

The invention is concerned with the use of a peptide comprising the N-terminal sequence

Pharmaceutical composition for treating haemorrhagic shock and its consecutive symptoms

The invention is directed to compounds and methods for prevention and/or treatment of inflammation using the same.

Compounds and methods for prevention and/or treatment of inflammation using the same

Therapeutic compositions can include modified peptides which are derived from the chain of the Bbeta(15-42)-fibrin fragment and wherein one or several of the amino acids of the sequence have been substituted by genetically encoded or not genetically encoded amino acids or peptidomimetics. They may exist as free peptides or as C-terminal derivative and/or being linked to a polyethylene glycol (PEG)-polymer, and have anti-inflammatory and/or endothelium stabilizing effects. Esters or amides may for instance be taken into consideration as C-terminal derivatives. Processes for production of the peptides and derivatives thereof are also described.

Peptides and peptide derivatives as well as pharmaceutical compositions containing the same

The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein Rand Rare either the same or different, wherein Rand Rare each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Zis selected from the group consisting of histidine and proline, wherein Zis selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation 

The present invention describes a novel immunodeficient rodent model comprising an organ graft, such as a human skin graft, said graft containing microvessels lined by endothelial cells, human T lymphocytes and, optionally, at least one agent capable of substantially depleting the rodent's Natural Killer cells. The human T lymphocytes are engrafted and circulating in the animal's blood, enabling interaction with the endothelial cells which can be allogenic to the donor for the skin graft. The immunodeficient rodent used can be a SCID mouse. Preferably, the endothelial cells are provided by grafting said human skin with an intact dermal superficial vascular plexus. This immunodeficient rodent can be used as a model for studying inflammatory human immune responses of the engrafted T lymphocytes to foreign antigen as well as for studying human allograft rejection, e.g. human microvessel destruction and the T cell-endothelial cell in vivo interactions associated with a human allograft rejection.

Growing community of inventors

Vienna, Austria

Peter Petzelbauer